NGF and early-onset autosomal dominant Alzheimer disease: Intracerebroventricular (ICV) administration of NGF has been proposed for several decades as a treatment for Alzheimer’s disease (AD) and clinical trials with NGF delivered by ICV administration have been performed [25]-[27].